Skip to main content

Teva Drives Positive Impact in Response to COVID-19 Pandemic

Recognizing our essential role in responding to the COVID-19 pandemic, we are doing all we can to ensure a sustainable supply of medicines and address the needs of patients and communities around the world.


During these uncertain times, Teva’s commitment to improve the lives of patients is steadfast. Our latest Environmental, Social and Governance (ESG) Statement provides information on:

  • Employee health and well-being
  • Employee engagement and enablement
  • Sustainable supply chain
  • COVID-19 donations and support for our communities
  • Governance (Board of Directors’ Risk Oversight)

Employee Health and Well-Being

We are operating conscientiously, focused on the health and safety of our employees.

We have reduced the number of people in our facilities to only those who are essential and may not work remotely. We are adhering to local social distancing recommendations, PPE and hygiene instructions to better protect our people, their families and the communities in which we operate.

We handle suspected and confirmed COVID-19 cases with the highest safety measures and with full respect for our employees' privacy.

Employee Engagement and Enablement

Our workforce is intact and united. We are keeping all of our employees fully employed, regardless of their location and profession.

We are attuned to the needs of our employees and managers, providing them with a variety of virtual solutions to help them deal with the disruption, new ways of working, and with their emotional needs.

Sustainable Supply Chain

We have measures in place to ensure supply continuity and sustainability, together with the safe transportation of our medicines and active pharmaceutical ingredients (API). Our supply chain remains largely uninterrupted and there is an adequate inventory of products across our network. We are closely monitoring the evolving situation in some of the key markets we produce and sell in, and are adapting our business continuity plans accordingly.

COVID-19 Donations and Support for Our Communities

Teva has continuously worked since the early days of the COVID-19 pandemic to support the efforts of governments and health services to curb the impact of the virus. Our global manufacturing network has been tirelessly focused on securing and scaling production of both API and finished doses for potential treatments that may prove essential in treating the condition.

We have donated nearly 18 million units of hydroxychloroquine and 500,000 units of azithromycin to more than 26 countries.

We have quickly mobilized to address emerging needs around the world, including:

  • United States: Donated more than10 million hydroxychloroquine doses to hospitals and refocused our Mount Sinai partnership, which supports patients with chronic conditions, towards coping with COVID-19.
  • Israel: Donated 2 million hydroxychloroquine units to the Ministry of Health, supported government-led programs to assist older people who may be isolated, and supported the Israeli National Aid Society.
  • China: Donated 9,600 packs of azithromycin to 15 hospitals in Hubei.
  • India: Provided medical supplies (personal protective equipment, kits, masks, thermometers, sanitization materials) and food to populations in need.
  • Spain: Donated 13,000 units of hydroxychloroquine, 15,000 masks and 7,000 gowns.
  • United Kingdom: Offered employees the opportunity to volunteer with the National Health Service (NHS) without having to use unpaid leave.

Globally: Paid for vacation days for employees not able to work on site or at home. 

Teva will continue to work with governments and international organizations throughout the world to support emerging needs related to this crisis, while doing everything possible to also continue to supply our vast portfolio of medicines to other patients.

Governance – Board of Directors Risk Oversight

Teva maintains a robust enterprise risk management system.  The Board oversees the Company’s risk assessment and risk management.  The Company’s annual risk assessment process includes both a top-down review of strategic risks and a bottom-up review of operational risks, all of which are presented to the Board. 

The Board has received reports from the outset of the COVID-19 crisis regarding the pandemic’s impact on the operations and performance of the Company. The Board has also been updated by senior management and this practice is intended to continue for the foreseeable future.

The Board oversees risk management policies, including operational risks relating to the Company’s business strategy and transactions.  Various committees assist the Board in this oversight responsibility, focusing on their respective areas of expertise. These committees regularly report to the full Board.  

To oversee response and alignment around COVID-19 management and mitigation efforts, the Company operates a global situation room at the corporate level, as well as regional, functional and local situation rooms to coordinate local responses.

Find out more